Acting on the cardiovascular system GLP-1 may have certain effects on the cardiovascular system, mainly manifested as increased heart rate and changes in blood pressure.Heart rate increase: The use of GLP-1 receptor agonists can cause an increase in heart rate in patients, and the magnitude of the increase in heart rate is related to the duration of GLP-1 action
Based on the mechanism of each component, the patients most likely to benefit from exploring KLOW with their physician are those who: Are actively on a GLP-1 receptor agonist (semaglutide, tirzepatide, retatrutide) and losing weight at a rate of 12+ lb/week Are experiencing visible skin laxity, facial volume loss, or skin texture changes as weight declines Have significant GI side effects (nausea, diarrhoea, mucosal discomfort) during dose escalation Carry known markers of systemic inflammation elevated hsCRP, elevated fasting insulin, or other metabolic biomarkers that have been flagged in prior lab work Are in their 40s or older, where baseline collagen decline makes the gap between demand and capacity most acute Have a history of inflammatory bowel conditions, slow wound healing, or joint/soft tissue injuries that have not fully resolved KLOW is less likely to be the primary tool for patients who are early in GLP-1 therapy, losing weight slowly, have no skin or GI symptoms, and carry no background inflammatory burden
But it only works if the reconstituted solution remains stable for the full 12 weeks
Ongoing support from our team can help you stay accountable, make adjustments as needed, and sustain your progress for lasting success
The stacks on this page are only prescribed after that evaluation confirms they are appropriate for the individual patient
On the other hand, liposomal glutathione has superior bioavailability due to liposome technology
